FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3216407617> ?p ?o ?g. }

• W3216407617 endingPage "362" @default.
• W3216407617 startingPage "349" @default.
• W3216407617 abstract "Aim: To report the Europe Ibrance Real World Insights study findings. Methods: Physicians abstracted demographic/clinical characteristics, treatment and outcomes data for women with HR+/HER2- locally advanced breast cancer (ABC) or metastatic breast cancer (MBC) receiving palbociclib + aromatase inhibitor (AI) or palbociclib + fulvestrant. Kaplan-Meier analysis estimated progression-free rates (PFRs) and survival rates (SRs). Results: 238 physicians abstracted data for 1723 patients. For patients (>90%) initiating at 125 mg/day, dose was reduced in 18.9% of palbociclib + AI and 12.3% of palbociclib + fulvestrant patients. At 12 months, PFR for palbociclib + AI was 88.1%, and SR was 97.3%; PFR for palbociclib + fulvestrant was 79.8%, and SR was 97.5%. Conclusion: Low dose-reduction rates and favorable PFRs and SRs suggest that palbociclib + AI/fulvestrant is well tolerated and effective for HR+/HER2- ABC/MBC in real-world clinical practice.Lay abstract We describe findings of the Europe Ibrance Real World Insights study. Patients were women with a common type of breast cancer that had worsened but not spread or that had spread. Doctors collected medical information about the women and looked at their progress while on treatment. The treatment was either palbociclib + an aromatase inhibitor or palbociclib + fulvestrant. Two hundred thirty-eight doctors collected information on 1723 women. More than 90% of women started this treatment at a dose of 125 mg/day; the dose was reduced for fewer than 20% of women. At 12 months, more than 80% of women survived without their breast cancer worsening, and more than 97% of women survived. These good results suggest that this treatment is safe and effective for women with breast cancer that had worsened but not spread or that had spread." @default.
• W3216407617 created "2021-12-06" @default.
• W3216407617 creator A5000518715 @default.
• W3216407617 creator A5019886822 @default.
• W3216407617 creator A5033267783 @default.
• W3216407617 creator A5039472267 @default.
• W3216407617 creator A5053714258 @default.
• W3216407617 creator A5055474032 @default.
• W3216407617 creator A5056433234 @default.
• W3216407617 date "2022-01-01" @default.
• W3216407617 modified "2023-10-17" @default.
• W3216407617 title "Real-world treatment of patients with palbociclib for HR+/HER2-advanced/metastatic breast cancer: the Europe IRIS study" @default.
• W3216407617 cites W1464936406 @default.
• W3216407617 cites W2134551201 @default.
• W3216407617 cites W2290950904 @default.
• W3216407617 cites W2474699717 @default.
• W3216407617 cites W2552099557 @default.
• W3216407617 cites W2795120383 @default.
• W3216407617 cites W2807968494 @default.
• W3216407617 cites W2808258662 @default.
• W3216407617 cites W2889646458 @default.
• W3216407617 cites W2897446380 @default.
• W3216407617 cites W2943438364 @default.
• W3216407617 cites W3009223368 @default.
• W3216407617 cites W3009807523 @default.
• W3216407617 cites W3014065682 @default.
• W3216407617 cites W3026068126 @default.
• W3216407617 cites W3121771782 @default.
• W3216407617 cites W3166403155 @default.
• W3216407617 doi "https://doi.org/10.2217/fon-2021-0716" @default.
• W3216407617 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34842454" @default.
• W3216407617 hasPublicationYear "2022" @default.
• W3216407617 type Work @default.
• W3216407617 sameAs 3216407617 @default.
• W3216407617 citedByCount "6" @default.
• W3216407617 countsByYear W32164076172022 @default.
• W3216407617 countsByYear W32164076172023 @default.
• W3216407617 crossrefType "journal-article" @default.
• W3216407617 hasAuthorship W3216407617A5000518715 @default.
• W3216407617 hasAuthorship W3216407617A5019886822 @default.
• W3216407617 hasAuthorship W3216407617A5033267783 @default.
• W3216407617 hasAuthorship W3216407617A5039472267 @default.
• W3216407617 hasAuthorship W3216407617A5053714258 @default.
• W3216407617 hasAuthorship W3216407617A5055474032 @default.
• W3216407617 hasAuthorship W3216407617A5056433234 @default.
• W3216407617 hasBestOaLocation W32164076171 @default.
• W3216407617 hasConcept C121608353 @default.
• W3216407617 hasConcept C126322002 @default.
• W3216407617 hasConcept C143998085 @default.
• W3216407617 hasConcept C2775930923 @default.
• W3216407617 hasConcept C2776166826 @default.
• W3216407617 hasConcept C2777176818 @default.
• W3216407617 hasConcept C2778504769 @default.
• W3216407617 hasConcept C2779744173 @default.
• W3216407617 hasConcept C2780482068 @default.
• W3216407617 hasConcept C29456083 @default.
• W3216407617 hasConcept C530470458 @default.
• W3216407617 hasConcept C71924100 @default.
• W3216407617 hasConceptScore W3216407617C121608353 @default.
• W3216407617 hasConceptScore W3216407617C126322002 @default.
• W3216407617 hasConceptScore W3216407617C143998085 @default.
• W3216407617 hasConceptScore W3216407617C2775930923 @default.
• W3216407617 hasConceptScore W3216407617C2776166826 @default.
• W3216407617 hasConceptScore W3216407617C2777176818 @default.
• W3216407617 hasConceptScore W3216407617C2778504769 @default.
• W3216407617 hasConceptScore W3216407617C2779744173 @default.
• W3216407617 hasConceptScore W3216407617C2780482068 @default.
• W3216407617 hasConceptScore W3216407617C29456083 @default.
• W3216407617 hasConceptScore W3216407617C530470458 @default.
• W3216407617 hasConceptScore W3216407617C71924100 @default.
• W3216407617 hasFunder F4320307765 @default.
• W3216407617 hasIssue "3" @default.
• W3216407617 hasLocation W32164076171 @default.
• W3216407617 hasLocation W32164076172 @default.
• W3216407617 hasOpenAccess W3216407617 @default.
• W3216407617 hasPrimaryLocation W32164076171 @default.
• W3216407617 hasRelatedWork W2292433415 @default.
• W3216407617 hasRelatedWork W2903143832 @default.
• W3216407617 hasRelatedWork W2931385471 @default.
• W3216407617 hasRelatedWork W2947775600 @default.
• W3216407617 hasRelatedWork W2978188358 @default.
• W3216407617 hasRelatedWork W3203690439 @default.
• W3216407617 hasRelatedWork W4200098175 @default.
• W3216407617 hasRelatedWork W4206711305 @default.
• W3216407617 hasRelatedWork W4226356606 @default.
• W3216407617 hasRelatedWork W4385420038 @default.
• W3216407617 hasVolume "18" @default.
• W3216407617 isParatext "false" @default.
• W3216407617 isRetracted "false" @default.
• W3216407617 magId "3216407617" @default.
• W3216407617 workType "article" @default.